Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences, Inc. (FBRX) is the subject of an Amendment No. 4 to a Schedule 13G filing in which Federated Hermes, Inc. and related reporting persons disclose that they no longer beneficially own Forte Biosciences common stock at or above reporting thresholds. The cover pages state 0 shares beneficially owned, with 0% of the class, and no sole or shared voting or dispositive power for each reporting person.
The amendment also notes that the reporting persons now fall under the category "Ownership of 5 percent or less of a class," with execution supported by multiple signatures from officers and trustees of Federated Hermes, Inc. and the Voting Shares Irrevocable Trust.